# Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

> **NCT07549698** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **CRISPR Therapeutics AG** · enrollment: 60 (estimated)

## Conditions studied

- Warm Autoimmune Hemolytic Anemia (WAIHA)
- ITP - Immune Thrombocytopenia
- Warm Autoimmune Hemolytic Anemia
- Immune Thrombocytopenic Purpura

## Interventions

- **BIOLOGICAL:** CTX112

## Key facts

- **NCT ID:** NCT07549698
- **Lead sponsor:** CRISPR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2033-12
- **Final completion:** 2033-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549698, "Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07549698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*